M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Association Between Gut Microbiome and Dietary Determinants and Vaccine Response

Recruiting

Conditions: Influenza

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-02-14

Last Posted Date: 2024-11-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1000

Registration Number: NCT05239403

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer

Phase 2

Recruiting

Conditions: Breast Carcinoma

Interventions: Procedure: Computed Tomography
Radiation: Fluorine F 18 Fluorthanatrace
Procedure: Positron Emission Tomography

First Posted Date: 2022-02-07

Last Posted Date: 2024-12-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 36

Registration Number: NCT05226663

Locations: 🇺🇸
Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States
🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Mobile Phone Text-based Intervention to Reduce Sedentary Behavior and Engage Communities on the Importance of Healthy Lifestyles: the TEXT2MOVE Study

Not Applicable

Recruiting

Conditions: Life Style
Healthy Lifestyle

Interventions: Device: FitBit

First Posted Date: 2022-02-01

Last Posted Date: 2024-10-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT05217108

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Oncology Dashboard for the Improvement of Operational Efficiency and Patients Outcomes in Patients With Sarcoma

Not Applicable

Active, not recruiting

Conditions: Sarcoma

Interventions: Other: Informational Intervention
Other: Best Practice
Other: Questionnaire Administration

First Posted Date: 2022-01-31

Last Posted Date: 2024-07-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 92

Registration Number: NCT05216029

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Trans-Pacific Multicenter Collaborative Study of Minimally Invasive Proximal Versus Total Gastrectomy for Proximal Gastric and Gastroesophageal Junction Cancers

Recruiting

Conditions: Gastric
Gastrostomy
GastroEsophageal Cancer

Interventions: Other: Standard of Care
Other: Control Group

First Posted Date: 2022-01-25

Last Posted Date: 2024-10-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 20

Registration Number: NCT05205343

Locations: 🇰🇷
Yonsei University College of Medicine, Soeul, Korea, Republic of
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇯🇵
Keio University School of Medicine, Tokyo, Japan

and more 1 locations

Positive Activities for Asian American Cancer Patients and Caregivers

Not Applicable

Completed

Conditions: Cancer

Interventions: Behavioral: Outside Contribution
Behavioral: Household Contribution
Behavioral: Control

First Posted Date: 2022-01-24

Last Posted Date: 2024-11-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT05203614

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Phase 1

Recruiting

Conditions: Metastases

Interventions: Drug: Yttrium-90 (Y-90) resin microspheres

First Posted Date: 2022-01-19

Last Posted Date: 2024-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT05195710

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Liver Cancer Prevention Randomized Control Trial

Not Applicable

Recruiting

Conditions: Liver Diseases
Cirrhosis, Liver
Fibrosis, Liver

Interventions: Behavioral: Intervention Group
Behavioral: Control Group

First Posted Date: 2022-01-19

Last Posted Date: 2024-10-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 266

Registration Number: NCT05196867

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

Phase 2

Withdrawn

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Breast Inflammatory Carcinoma
Invasive Breast Carcinoma
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8

Interventions: Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Biological: Panitumumab
Biological: Pembrolizumab

First Posted Date: 2022-01-05

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05177796

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Molecular Epidemiology of Biliary Tree Cancers

Recruiting

Conditions: Cholangiocarcinoma
Malignant Digestive System Neoplasm

Interventions: Procedure: Biospecimen Collection
Other: Questionnaire Administration

First Posted Date: 2022-01-05

Last Posted Date: 2024-11-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1500

Registration Number: NCT05179486

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy